論文・技術情報追加のお知らせ

1. Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.

CAR-T療法の血液・リンパ系副作用が致命的

対象DB：FAERS

2. Impact of Proton Pump Inhibitors on Osimertinib-Induced Cardiotoxicity in NSCLC Patients.

オシメルチニブとPPI併用で心毒性リスク増加

対象DB：FAERS

3. Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database.

15薬剤が白内障の独立リスク因子として特定

対象DB：FAERS

4. Comparison of Adverse Events Among Angiotensin Receptor Blockers in Hypertension Using the United States Food and Drug Administration Adverse Event Reporting System.

ARBsによる副作用の違い、個別化治療が重要

対象DB：FAERS

5. Pharmacovigilance analysis of small bowel bleeding associated with NSAIDs.

NSAIDsと小腸出血の関連、予防効果の可能性

対象DB：FAERS,JADER

6. Real-World Safety Profile of Cenegermin Per FDA Adverse Event Reporting System.

セネゲルミン使用で眼の痛みや刺激が多発

対象DB：FAERS

7. Dupilumab Use in Eosinophilic Esophagitis: Analysis of the FDA Adverse Event Reporting System Database.

デュピルマブの食道炎治療に関するFAERS分析

対象DB：FAERS

8. Challenges with using the FDA Adverse Event Reporting System to evaluate risk of benzoyl peroxide containing products.

FDAの副作用報告システムでベンゾイル過酸化物製品のリスク評価に課題

対象DB：FAERS

9. Identification of drug combinations to reduce the risk of pioglitazone-related bladder cancer using the FDA adverse event reporting system database.

ピオグリタゾンと膀胱癌のリスクに関する解析

対象DB：FAERS

10. Corneal Complications: Drug-Induced Deposits and Food and Drug Administration Adverse Event Reporting System Data Insights-A Retrospective Study.

薬剤による角膜沈着の発生と関連薬剤の解析

対象DB：FAERS

11. Pharmacovigilance and Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN): 55 Years of Retrospective Analysis of the FDA Adverse Event Reporting System (FAERS) Database.

SJS/TENの薬剤関連リスクと報告傾向の分析

対象DB：FAERS

12. Risk factors for drug-related non-infectious pneumonia: insights from the FDA adverse event reporting system (FAERS).

非感染性肺炎は薬剤による重篤な副作用で、早期発見が重要

対象DB：FAERS

13. Focusing on spinal stenosis: emerging discoveries concerning Alendronate-induced risks and genetic drug targets.

アレンドロン酸は脊柱管狭窄症のリスクを高める可能性

対象DB：FAERS

14. Unveiling the differences: infection disorders associated with tumor necrosis factor alpha inhibitors in pediatric patients-a pharmacovigilance study (2004-2023).

TNFiは小児において感染症関連ADRのリスクが高い

対象DB：FAERS

15. Sex differences in suspected adverse drug reactions of anti-seizure medications reported in EudraVigilance.

男性は重篤・致死的ADRが多く回復傾向も

対象DB：EudraVigilance

16. Non-genetic factors associated with ACE-inhibitor and angiotensin receptor blocker-induced angioedema.

高齢・喫煙・アレルギーがAEのリスク因子

対象DB：EudraVigilance

17. Comprehensive analysis of adverse event profile changes with pertuzumab addition to trastuzumab-based breast cancer therapy: Disproportionality analysis using VigiBase.

パートツズマブ併用で下痢など有害事象が増加

対象DB：VigiBase

18. Safety of ifosfamide during pregnancy: A comprehensive analysis.

イホスファミドは胎児腎毒性のリスクがある

対象DB：FPVD,VigiBase

19. Thromboembolic and infectious complication risks in TKA and UKA: evidence from a Japanese nationwide cohort.

TKAはUKAより合併症リスクが高い

対象DB：DPC

20. Increasing utilization of total ankle arthroplasty in Japan: Trends and regional variations over 12 Years from a national database.

人工足関節置換術が増加し地域差あり

対象DB：DPC

21. In-Hospital Mortality after Bronchoscopy in Patients Receiving Direct Oral Anticoagulants and Those Who Were Not: A Matched-pair Cohort Study Using A Nationwide Japanese Inpatient Database.

DOAC使用群は死亡率と合併症が高率

対象DB：DPC

22. The burden of hand trauma surgery on primary care in the United Kingdom: a nation-wide analysis of antibiotic and opioid prescriptions.

術後90日でSSI治療率は14.4%に達した

対象DB：CPRD

23. HbA1c variability and all-cause mortality in type 1 and type 2 diabetes: A population-based cohort study using electronic health records.

HbA1cの変動大は死亡率上昇と関連

対象DB：CPRD

24. Mortality risk following ischaemic and non-ischaemic heart failure in people with type 2 diabetes: Observational study in England, 2000-2021.

糖尿病は虚血・非虚血性心不全の死亡率を上昇

対象DB：CPRD

25. New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada.

カナダでワクチン後の感覚異常が多く報告

対象DB：CVAR